Li Yu
Impact in
-
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
- Oncology top 5%
- Lung Cancer Research Studies
Papers in
-
- Cancer therapeutics and mechanisms 4
- Glycosylation and Glycoproteins Research 2
-
- Lung Cancer Treatments and Mutations 10
- Co-authors
- Peter N. Morcos (7 shared papers)Yanqing Zang (1 shared paper)Kiharu Igarashi (1 shared paper)Gregory J. Riely (1 shared paper)Sophie Golding (1 shared paper)Tomohiro Tanaka (1 shared paper)Shirish M. Gadgeel (1 shared paper)Howard West (1 shared paper)
- Journals
- Xenobiotica (3 papers)Investigational New Drugs (2 papers)Annals of Oncology (2 papers)Frontiers in Immunology (2 papers)Frontiers in Cardiovascular Medicine (2 papers)
- Partner nations
- ChinaUnited StatesSwitzerland
In The Last Decade
Li Yu
73 papers receiving 1.8k citations
Li Yu's Hit Papers
Peers
Comparison fields: 5 of 120
- Pulmonary and Respiratory Medicine 651
- Oncology 551
- Pharmacology 115
- Genetics 106
- Molecular Biology 560
Countries citing papers authored by Li Yu
This map shows the geographic impact of Li Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Yu more than expected).
Fields of papers citing papers by Li Yu
This network shows the impact of papers produced by Li Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Yu. The network helps show where Li Yu may publish in the future.
Co-authors
The 25 scholars most cited alongside Li Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study Hit paper breakdown → | 2014 | 541 |
| 2 | 2007 | 152 | |
| 3 | 2016 | 136 | |
| 4 | 2007 | 79 | |
| 5 | 2020 | 66 | |
| 6 | 2005 | 54 | |
| 7 | 2016 | 54 | |
| 8 | 2013 | 46 | |
| 9 | 2004 | 46 | |
| 10 | 2018 | 41 | |
| 11 | 2016 | 38 | |
| 12 | 2008 | 35 | |
| 13 | 1997 | 32 | |
| 14 | 2021 | 28 | |
| 15 | 2010 | 28 | |
| 16 | 2017 | 26 | |
| 17 | 2023 | 25 | |
| 18 | 2016 | 24 | |
| 19 | 2016 | 24 | |
| 20 | 2018 | 23 |
About Li Yu
Li Yu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Surgery and Pathology and Forensic Medicine, having authored 75 papers that have together received 1.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), Pancreatic and Hepatic Oncology Research (5 papers), Cancer therapeutics and mechanisms (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Pancreatitis Pathology and Treatment (3 papers), Glycosylation and Glycoproteins Research (2 papers), Pregnancy and preeclampsia studies (2 papers) and Reproductive System and Pregnancy (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (651 citations), Oncology (551 citations), Pharmacology (115 citations), Genetics (106 citations) and Molecular Biology (560 citations). Li Yu has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include Peter N. Morcos, Yanqing Zang, Kiharu Igarashi, Gregory J. Riely, Sophie Golding, Tomohiro Tanaka, Shirish M. Gadgeel, Howard West, Leena Gandhi and Sai‐Hong Ignatius Ou. Their work appears in journals such as Xenobiotica, Investigational New Drugs, Annals of Oncology, Frontiers in Immunology and Frontiers in Cardiovascular Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.